In the preceding three months, 14 analysts have released ratings for Penumbra PEN, presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 7 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 5 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Penumbra and provided 12-month price targets. The average target is $306.86, accompanied by a high estimate of $340.00 and a low estimate of $260.00. Surpassing the previous average price target of $273.91, the current average has increased by 12.03%.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Travis Steed | B of A Securities | Announces | Buy | $320.00 | - |
| Robert Marcus | JP Morgan | Raises | Overweight | $285.00 | $230.00 |
| David Rescott | Truist Securities | Raises | Buy | $325.00 | $285.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $313.00 | $285.00 |
| Jason Mills | Canaccord Genuity | Raises | Buy | $340.00 | $323.00 |
| Priya Sachdeva | UBS | Raises | Buy | $320.00 | $305.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $305.00 | $275.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $330.00 | $250.00 |
| Kallum Titchmarsh | Morgan Stanley | Raises | Equal-Weight | $260.00 | $240.00 |
| David Rescott | Baird | Raises | Outperform | $328.00 | $305.00 |
| David Rescott | Baird | Raises | Outperform | $305.00 | $275.00 |
| Priya Sachdeva | UBS | Announces | Buy | $305.00 | - |
| Richard Newitter | Truist Securities | Raises | Buy | $285.00 | $240.00 |
| Steve Lichtman | Oppenheimer | Announces | Outperform | $275.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Penumbra. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Penumbra compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Penumbra's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Penumbra analyst ratings.
Get to Know Penumbra Better
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Penumbra: Delving into Financials
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Penumbra displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.83%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.99%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Penumbra's ROA excels beyond industry benchmarks, reaching 2.24%. This signifies efficient management of assets and strong financial health.
Debt Management: Penumbra's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.19.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
